Rimantadine
From Proteopedia
(Difference between revisions)
| Line 14: | Line 14: | ||
{| class="wikitable" border="1" width="52%" style="text-align:center" | {| class="wikitable" border="1" width="52%" style="text-align:center" | ||
|- | |- | ||
| - | ! colspan="7" align="center"| M2 Proton Channel Inhibitor [[Pharmaceutical_Drugs#Pharmacokinetics_Translated|Pharmacokinetics]]<ref>PMID:3662473</ref> | + | ! colspan="7" align="center"| M2 Proton Channel Inhibitor [[Pharmaceutical_Drugs#Pharmacokinetics_Translated|Pharmacokinetics]]<ref>PMID:3662473</ref><ref>PMID:17156962</ref> |
|- | |- | ||
! Parameter | ! Parameter | ||
| Line 22: | Line 22: | ||
! [[Pharmaceutical_Drugs#Tmax|T<sub>max</sub>]] (hr) | ! [[Pharmaceutical_Drugs#Tmax|T<sub>max</sub>]] (hr) | ||
! 4.3 | ! 4.3 | ||
| - | ! | + | ! 2.5 |
|- | |- | ||
! [[Pharmaceutical_Drugs#Cmax|C<sub>max</sub>]] (ng/ml) | ! [[Pharmaceutical_Drugs#Cmax|C<sub>max</sub>]] (ng/ml) | ||
! 310 | ! 310 | ||
| - | ! | + | ! 402 |
|- | |- | ||
! [[Pharmaceutical_Drugs#Bioavailability_.28F.29|Bioavailability]] (%) | ! [[Pharmaceutical_Drugs#Bioavailability_.28F.29|Bioavailability]] (%) | ||
| Line 42: | Line 42: | ||
! [[Pharmaceutical_Drugs#Area_Under_the_Curve_.28AUC.29|AUC]] (ng/ml/hr) | ! [[Pharmaceutical_Drugs#Area_Under_the_Curve_.28AUC.29|AUC]] (ng/ml/hr) | ||
! 11917 | ! 11917 | ||
| - | ! | + | ! 5420 |
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
|- | |- | ||
! Dosage (mg) | ! Dosage (mg) | ||
! 100 | ! 100 | ||
| - | ! | + | ! 100 |
|- | |- | ||
! Metabolism | ! Metabolism | ||
| - | ! | + | ! Negligible |
| - | ! | + | ! Negligible |
|} | |} | ||
Revision as of 12:36, 6 December 2010
|
Better Known as: Flumadine
- Marketed By: Forest Labs
- Major Indication: Influenza Infection
- Drug Class: M2 Proton Channel Inhibitor
- Date of FDA Approval (Patent Expiration): 1993 (2001)
- 1994 Sales: N/A
- Importance: One of the the first treatments for Influenza Infections. Since 1994, nearly 100% of influenza viruses had developed resistance to rimantadine, and it is no longer recommended as a treatment for the flu.
- The following is a list of Pharmacokinetic Parameters. See: Pharmaceutical Drugs for more information
Mechanism of Action
Pharmacokinetics
| M2 Proton Channel Inhibitor Pharmacokinetics[1][2] | ||||||
|---|---|---|---|---|---|---|
| Parameter | Rimantadine | Amantadine | ||||
| Tmax (hr) | 4.3 | 2.5 | ||||
| Cmax (ng/ml) | 310 | 402 | ||||
| Bioavailability (%) | >90 | >90 | ||||
| Protein Binding (%) | 40 | 67 | ||||
| T1/2 (hr) | 27.7 | ~15 | ||||
| AUC (ng/ml/hr) | 11917 | 5420 | ||||
| Dosage (mg) | 100 | 100 | ||||
| Metabolism | Negligible | Negligible | ||||
References
- ↑ Anderson EL, Van Voris LP, Bartram J, Hoffman HE, Belshe RB. Pharmacokinetics of a single dose of rimantadine in young adults and children. Antimicrob Agents Chemother. 1987 Jul;31(7):1140-2. PMID:3662473
- ↑ Wang P, Liang YZ, Chen BM, Zhou N, Yi LZ, Yu Y, Yi ZB. Quantitative determination of amantadine in human plasma by liquid chromatography-mass spectrometry and the application in a bioequivalence study. J Pharm Biomed Anal. 2007 Mar 12;43(4):1519-25. Epub 2006 Dec 6. PMID:17156962 doi:10.1016/j.jpba.2006.10.044
